(600789)"Shandong Lukang Pharmaceutical Co., Ltd."Report for Q3 2026
Filed with SSE · Stock code 600789 · · 11 pages · Chinese
Summary by 6ix AI
The report indicates a decline in revenue and net profit compared to the same period last year, with significant decreases in several key financial metrics. The company assures that the report's content is accurate and complete, and it has not been audited.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries
Shandong Lukang Pharmaceutical Co., Ltd. on 6ix
Earlier from Shandong Lukang Pharmaceutical
- (600789)"Shandong Lukang Pharmaceutical Co., Ltd."Announcement on Resignation of Director and Election of Employee Representative Director
- (600789)"Shandong Lukang Pharmaceutical Co., Ltd."Announcement on Resolutions of the 17th (Extraordinary) Meeting of the 11th Board of Directors
- (600789)"Shandong Lukang Pharmaceutical Co., Ltd."Announcement on Obtaining Drug Registration Certificate
- (600789)"Shandong Lukang Pharmaceutical Co., Ltd."Announcement on Adjustment to Certain Senior Executives
- Announcement on Change of the Signing Certified Public Accountant
Follow Shandong Lukang Pharmaceutical into a list and get an email when it puts out news.
Follow Shandong Lukang Pharmaceutical